• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾病中的血浆醛固酮浓度

Plasma aldosterone concentrations in chronic renal disease.

作者信息

Hené R J, Boer P, Koomans H A, Mees E J

出版信息

Kidney Int. 1982 Jan;21(1):98-101. doi: 10.1038/ki.1982.14.

DOI:10.1038/ki.1982.14
PMID:7043053
Abstract

The disagreement in the literature concerning the role of aldosterone in the maintenance of potassium homeostasis in chronic renal disease might be partially explained by differences in plasma renin activity (PRA) among individual patients. Therefore, a study was done in 28 selected patients with varying degrees of renal insufficiency whose serum potassium and PRA concentrations were within the normal range. The results indicate that at comparable serum potassium and PRA concentrations, plasma aldosterone is in most instances elevated when creatinine clearance is lower than 50% of normal.

摘要

文献中关于醛固酮在慢性肾病钾稳态维持中作用的分歧,可能部分归因于个体患者血浆肾素活性(PRA)的差异。因此,对28例选定的肾功能不全程度各异且血清钾和PRA浓度在正常范围内的患者进行了一项研究。结果表明,在血清钾和PRA浓度相当的情况下,当肌酐清除率低于正常的50%时,大多数情况下血浆醛固酮会升高。

相似文献

1
Plasma aldosterone concentrations in chronic renal disease.慢性肾病中的血浆醛固酮浓度
Kidney Int. 1982 Jan;21(1):98-101. doi: 10.1038/ki.1982.14.
2
Role of the renin-angiotensin-aldosterone system in the regulation of plasma potassium in chronic renal disease.
Nephron. 1975;15(1):35-49. doi: 10.1159/000180491.
3
Relation between plasma aldosterone concentration and renal handling of sodium and potassium, in particular in patients with chronic renal failure.
Nephron. 1984;37(2):94-9. doi: 10.1159/000183221.
4
[Aldosteroneia in acute kidney failure].
Z Gesamte Inn Med. 1976 Mar 1;31(5):144-8.
5
[Changes in the activity of plasma renin and blood aldosterone and in that of the enzyme converting angiotensin I to angiotensin II during the dialytic treatment of patients with chronic renal insufficiency].[慢性肾功能不全患者透析治疗期间血浆肾素活性、血醛固酮及血管紧张素I转换为血管紧张素II的酶活性的变化]
Cardiologia. 1985 Jul;30(7):505-10.
6
[The regulation of plasma aldosterone in hemodialysis patients].[血液透析患者血浆醛固酮的调节]
Schweiz Med Wochenschr. 1980 Dec 6;110(49):1882-4.
7
Regulations of plasma aldosterone in young hyperkalemic patients with stable chronic renal failure.
Endokrinologie. 1979 Apr;73(2):173-85.
8
Response of plasma aldosterone to sequential ultrafiltration, dialysis and conventional hemodialysis.
Nephron. 1980;26(6):274-9. doi: 10.1159/000182001.
9
Control of aldosterone responsiveness in terminal renal failure.
Kidney Int. 1975 May;7(5):351-7. doi: 10.1038/ki.1975.48.
10
[Activity of plasma renin and plasma aldosterone in terminal renal failure].
Schweiz Med Wochenschr. 1974 Dec 7;104(49):1799-801.

引用本文的文献

1
Impaired aldosterone response to potassium and hyperkalemia in patients receiving a renin-angiotensin-aldosterone system inhibitor.接受肾素-血管紧张素-醛固酮系统抑制剂治疗的患者对钾的醛固酮反应受损及高钾血症
Korean J Intern Med. 2025 May;40(3):468-481. doi: 10.3904/kjim.2024.160. Epub 2025 Apr 30.
2
Efficacy of Mineralocorticoid Receptor Antagonists on Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: An Umbrella Review.盐皮质激素受体拮抗剂对慢性肾脏病患者肾脏和心血管结局的疗效:一项伞状综述
Kidney Med. 2024 Dec 13;7(2):100943. doi: 10.1016/j.xkme.2024.100943. eCollection 2025 Feb.
3
Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists.
亚洲和非亚洲慢性肾脏病和 2 型糖尿病患者应用非甾体类盐皮质激素拮抗剂的肾脏效应和安全性。
J Diabetes. 2024 Jun;16(6):e13566. doi: 10.1111/1753-0407.13566.
4
Cardiorenal Syndromes and Their Role in Water and Sodium Homeostasis.心肾综合征及其在水钠平衡中的作用。
Physiol Res. 2024 Apr 30;73(2):173-187. doi: 10.33549/physiolres.935110.
5
Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists.醛固酮受体过度激活:用非甾体类醛固酮受体拮抗剂靶向全身影响。
Diabetologia. 2024 Feb;67(2):246-262. doi: 10.1007/s00125-023-06031-1. Epub 2023 Dec 21.
6
Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist.非奈利酮:问答——关于新型有前景的非甾体盐皮质激素受体拮抗剂的四大基本论点
J Clin Med. 2023 Jun 12;12(12):3992. doi: 10.3390/jcm12123992.
7
A case of primary aldosteronism with excessive secretion of renin that was unmasked by kidney transplantation.一例肾移植术后肾素过度分泌导致的原发性醛固酮增多症。
CEN Case Rep. 2024 Feb;13(1):1-8. doi: 10.1007/s13730-023-00784-9. Epub 2023 Apr 3.
8
Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis.在 2 型糖尿病和肾脏结局中:一项随机效应模型荟萃分析。
Front Endocrinol (Lausanne). 2023 Jan 20;14:1114894. doi: 10.3389/fendo.2023.1114894. eCollection 2023.
9
Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.盐皮质激素受体拮抗剂在治疗2型糖尿病相关慢性肾脏病中的进展
Mayo Clin Proc Innov Qual Outcomes. 2022 Oct 15;6(6):536-551. doi: 10.1016/j.mayocpiqo.2022.09.002. eCollection 2022 Dec.
10
Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.临床视角——盐皮质激素受体拮抗剂在慢性肾脏病合并2型糖尿病患者中的循证进展
Kidney Int Suppl (2011). 2022 Apr;12(1):27-35. doi: 10.1016/j.kisu.2021.11.005. Epub 2022 Mar 18.